Radiation and immunotherapy for advanced cancer
Part of Cancer clinical trials.
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread or come back, confirmed by a doctor or medical records.
- Your cancer has gotten worse after standard treatment, or you cannot tolerate standard treatment, or you choose not to have it.
- You have at least one tumor that can be treated with high-dose radiation (SBRT) and one that can be treated with low-dose radiation (LDRT).
- Your overall health is fair (ECOG score 0-2) and your doctor expects you to live longer than 3 months.
- You have not had a serious immune reaction to an immunotherapy drug in the past that forced you to stop it permanently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.